A view of the brand of Novo Nordisk on the firm’s workplace in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little | Reuters
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical big reported constructive early-stage outcomes for its as soon as weekly amycretin weight problems drug.
The trial confirmed that the therapy, which is run by way of injection, resulted in common weight discount of twenty-two% in overweight and chubby sufferers after 36 weeks.
Shares had been final up 10% at 11:43 a.m. London time, placing the inventory on target for its greatest day by day achieve since August 2023. Shares of fellow Danish weight problems drug maker Zealand Pharma additionally tracked increased, final up 4.7%.
Amycretin targets the identical intestine hormone that Wegovy mimics, often known as GLP-1, in addition to a pancreas hormone referred to as amylin that impacts starvation. Wegovy is Novo Nordisk’s flagship weight problems drug whereas Ozempic is its diabetes therapy.
The trial was carried out on 125 chubby or overweight sufferers and the most typical uncomfortable side effects had been gastrointestinal, with the overwhelming majority being “delicate to average in severity.”
“We’re very inspired by the subcutaneous section 1b/2a outcomes for amycretin in folks residing with chubby or weight problems,” Martin Lange, government vice chairman for improvement at Novo Nordisk, mentioned in an announcement.
“The outcomes seen within the trial assist the burden decreasing potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that now we have beforehand seen with the oral formulation.”
Novo can be creating an amycretin weight problems tablet. Early-stage trials introduced in September, confirmed common weight lack of 13.1% after 12 weeks. The corporate mentioned on the time that the therapy was protected and tolerable for sufferers, however included mild-to-moderate uncomfortable side effects.
It is a creating story. Please verify again for updates.
